Anticipation is rising for the European Society’s Annual Congress, an event like no other, providing access to ground-breaking science, essential clinical updates and the chance to interact with a renowned international faculty. With over 125,000 attendees last year, the bar was set high for ESC 2021.
Kicking off this week from August 27-30, ESC 2021 has highly anticipated presentations on the advancements in the understanding and management of heart failure. Here are a handful:
Friday, August 27, 2021; 4:30 AM–5:15 PM
DAPA-HF: update on dapagliflozin and prevention of adverse-outcomes in heart failure and reduced ejection fraction with and without T2D compared with placebo. J Curtain
Friday, August 27, 2021; 8:30 AM–9:00 PM
GUIDE-HF: hemodynamic-guided management of heart failure – randomized arm primary outcomes. J Lindenfeld
Friday, August 27, 2021; 11:55 AM–12:40 PM
EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalizations in patients with heart failure with a preserved ejection fraction, with and without diabetes. S Anker
Sunday, August 29, 2021: 8:00 AM–8:30 AM
TOMAHAWK: immediate angiography after out-of-hospital cardiac arrest. S Desch
Monday, August 30, 2021; 11:25 AM–11:55 AM
STEP Study: intensive vs. standard blood pressure control among older hypertensive patients. J Cai
Other presentations on heart failure include–but are far from limited to–the HUNT for HF risk score (HUNT4HF); efficacy and sustainability of remote patient management in HF; postimplant phosphodiesterase type 5 inhibitor use in contemporary centrifugal flow left ventricular assist; MIdazolam versus MOrphine in acute cardiogenic pulmonary edema; efficacy of ARNI in real-world, and more!
Stay tuned for regular updates on the latest news released at ESC 2021 in Heart Failure in our Physician’s Weekly Conference Coverage series.
Visit ESC Congress 2021 for more information or register here.
